Sagimet Biosciences Inc. (SGMT) Stock Price & Analysis
Sagimet Biosciences Inc. (SGMT) rose 0.86% to USD 7.07 as of July 26, 2026 at 11:57 UTC, according to Nexqual real-time market data.
SGMT last closed at USD 7.01; the session ranged USD 6.86–7.2 on volume of 889,994 shares. Market capitalization is $436.59M, with a 52-week range of USD 4.5–10.46 (NGM). Source: Nexqual, July 26, 2026 at 11:57 UTC.
Key Statistics (as of July 26, 2026 at 11:57 UTC)
| Price | USD 7.07 |
|---|---|
| Change | ▲ 0.86% (up) |
| Previous Close | USD 7.01 |
| Open | USD 7.14 |
| Day Range | USD 6.86 – 7.2 |
| 52-Week Range | USD 4.5 – 10.46 |
| Volume | 889,994 shares |
| Market Cap | $436.59M |
| Exchange | NGM |
Technical Analysis (SGMT)
Nexqual's technical model rates SGMT "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 11:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.4 (neutral) |
| vs SMA50 | Below (USD 7.1) |
| MACD | 0.02 (positive) |
Analyst Ratings (SGMT)
Wall Street analysts rate SGMT "Strong Buy" based on 10 analysts, with a mean price target of USD 26.2 (range USD 8–49), per Nexqual as of July 26, 2026 at 11:57 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 26.2 |
| High Target | USD 49 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (SGMT)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.27 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.33 vs est -0.35 ▲ beat |
| 2025-12-31 | USD -0.29 vs est -0.4 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -0.39 ▼ miss |
| 2025-06-30 | USD -0.32 vs est -0.5 ▲ beat |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
Financials & Fundamentals (SGMT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -36.04% |
| Debt / Equity | 0.04 |
| Current Ratio | 20.34 |
| Total Cash | $104.54M |
| Total Debt | $39,000 |
| Free Cash Flow | $-27.20M |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
Financial Health Score (SGMT)
Nexqual rates Sagimet Biosciences Inc.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 11:57 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $105M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$40M |
| Efficiency | Critical — ROE -36%, ROA -24.0% |
Ownership (SGMT)
| Insider Ownership | +3.37% |
|---|---|
| Institutional Ownership | +22.77% |
| Shares Outstanding | 61.18M |
| Float | 59.00M |
| Short % of Float | +16.06% |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
Leadership (SGMT)
Sagimet Biosciences Inc. is led by David A. Happel (age 63), CEO, President & Director, per Nexqual as of July 26, 2026 at 11:57 UTC.
| CEO, President & Director | David A. Happel (age 63) |
|---|---|
| CFO & Principal Accounting Officer | Thierry Chauche (age 49) |
| Chief Scientific Officer | Marie O'Farrell |
| Senior Vice President of New Products | Robert D'Urso |
Major Backers & Investors (SGMT)
Notable institutional backers of Sagimet Biosciences Inc. include Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund, Woodline Partners LP, Marshall Wace LLP, according to Nexqual as of July 26, 2026 at 11:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 6.51% |
| Woodline Partners LP | 3.13% |
| Marshall Wace LLP | 3.02% |
| Baker Bros. Advisors, LP | 2.98% |
| Affinity Asset Advisors, Llc | 2.71% |
| Millennium Management | 2.69% |
| HHLR Advisors, LTD | 2.26% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.77% |
| BlackRock | 3.98% |
| State Street | 3.06% |
Source: Nexqual, July 26, 2026 at 11:57 UTC.
From Sagimet Biosciences Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- These trials would allow us to evaluate potential improvements in non-invasive biomarkers directly in MASH patients and select combinations for further development.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TVGN | Tevogen Bio Holdings Inc. | USD 4.49 | ▲ 5.9% |
| BDRX | Biodexa Pharmaceuticals plc | USD 1.65 | ▼ 3.51% |
| LRHC | La Rosa Holdings Corp. | USD 0.97 | ▲ 5.87% |
| INBS | Intelligent Bio Solutions Inc. | USD 1.75 | ▼ 2.78% |
| TNON | Tenon Medical, Inc. | USD 0.19 | ▼ 3.65% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:57 UTC. This page is informational and not investment advice.